OptoRhythm LTD

OptoRhythm is pioneering a novel, light-based approach to heart rhythm management. Founded on over 20 years of groundbreaking research by Prof. Lior Gepstein (CSO & Co-Founder), a global leader in cardiac electrophysiology and optogenetics, OptoRhythm is transforming Atrial Fibrillation (AF) treatment. Our technology combines optogenetic gene therapy with an implantable micro-LED array to create the world’s first Optic Defibrillator. Unlike traditional electric shock methods, OptoRhythm’s Optic Defibrillator painlessly stops chaotic atrial contractions using precise light pulses. This real-time, repeatable, non-destructive solution addresses current AF treatment limitations and will provide long-term rhythm control as well as improved patient’s outcomes and reduced AF burden.